Marjorie Perloff

5.5k total citations · 2 hit papers
112 papers, 3.1k citations indexed

About

Marjorie Perloff is a scholar working on Literature and Literary Theory, Molecular Biology and Philosophy. According to data from OpenAlex, Marjorie Perloff has authored 112 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Literature and Literary Theory, 18 papers in Molecular Biology and 17 papers in Philosophy. Recurrent topics in Marjorie Perloff's work include Poetry Analysis and Criticism (23 papers), Wittgensteinian philosophy and applications (12 papers) and Estrogen and related hormone effects (9 papers). Marjorie Perloff is often cited by papers focused on Poetry Analysis and Criticism (23 papers), Wittgensteinian philosophy and applications (12 papers) and Estrogen and related hormone effects (9 papers). Marjorie Perloff collaborates with scholars based in United States, United Kingdom and Italy. Marjorie Perloff's co-authors include James A. Crowell, Victoria Brown, William P. Steward, Andreas J. Gescher, Tristan D. Booth, Ketan Patel, Dean E. Brenner, Karen Brown, Murray P. Ducharme and Guy Faust and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and American Journal of Clinical Nutrition.

In The Last Decade

Marjorie Perloff

84 papers receiving 2.8k citations

Hit Papers

Phase I Dose Escalation Pharmacokinetic Study in Healthy ... 2007 2026 2013 2019 2007 2010 200 400 600

Peers

Marjorie Perloff
Charles R. Evans United States
Yian Wang United States
Ming Ji China
Bo Wu China
Michael J. MacDonald United States
Hyun Joon Kim South Korea
Martin Carrier United Kingdom
Marjorie Perloff
Citations per year, relative to Marjorie Perloff Marjorie Perloff (= 1×) peers Catherine A. O’Brian

Countries citing papers authored by Marjorie Perloff

Since Specialization
Citations

This map shows the geographic impact of Marjorie Perloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marjorie Perloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marjorie Perloff more than expected).

Fields of papers citing papers by Marjorie Perloff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marjorie Perloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marjorie Perloff. The network helps show where Marjorie Perloff may publish in the future.

Co-authorship network of co-authors of Marjorie Perloff

This figure shows the co-authorship network connecting the top 25 collaborators of Marjorie Perloff. A scholar is included among the top collaborators of Marjorie Perloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marjorie Perloff. Marjorie Perloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heckman‐Stoddard, Brandy M., Jill P. Crandall, Sharon L. Edelstein, et al.. (2025). Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. Cancer Prevention Research. 18(7). 401–411. 3 indexed citations
2.
Deng, Nan, Laura Reyes-Uribe, Edwin R. Parra, et al.. (2023). Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa. Frontiers in Immunology. 14. 1162669–1162669. 3 indexed citations
3.
Patel, Anisha B., J. Jack Lee, Diane D. Liu, et al.. (2022). Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer. Cancer Prevention Research. 16(1). 47–55. 4 indexed citations
4.
Armstrong, William B., Thomas H. Taylor, Ann R. Kennedy, et al.. (2013). Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial. Cancer Prevention Research. 6(5). 410–418. 47 indexed citations
5.
Perloff, Marjorie. (2013). La Grande Permission: John Ashbery in the 21st Century. 1(2). 1 indexed citations
6.
Reid, Joel M., Chad A. Walden, Rui Qin, et al.. (2011). Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prevention Research. 4(3). 347–353. 16 indexed citations
7.
Stanton, Domna C., Marjorie Perloff, Michael Holquist, et al.. (2005). MLA volume 120 issue 1 Cover and Front matter. PMLA/Publications of the Modern Language Association of America. 120(1). f1–f4. 1 indexed citations
8.
Perloff, Marjorie. (2001). Reading Gass Reading Rilke. 25. 486.
9.
Perloff, Marjorie. (2000). Removing the Eggshells: Rereading Wittgenstein on a Desert Island. Genre. 33(3-4). 269–277. 1 indexed citations
10.
Perloff, Marjorie. (1998). 'Logocinema of the Frontiersman': Eugene Jolas's Multilingual Poetics and its Legacies. Research Online (University of Wollongong). 20(3). 43. 2 indexed citations
11.
McMillan, John, et al.. (1996). Plasma alpha-tocopherol concentrations after supplementation with water- and fat-soluble vitamin E. American Journal of Clinical Nutrition. 64(3). 329–335. 13 indexed citations
12.
Tross, Susan, Alice B. Kornblith, David Cella, et al.. (1996). Psychological Symptoms and Disease-Free and Overall Survival in Women With Stage II Breast Cancer. JNCI Journal of the National Cancer Institute. 88(10). 661–667. 81 indexed citations
13.
Kelloff, Gary J., et al.. (1993). Development of chemopreventive agents for lung and upper aerodigestive tract cancers. Journal of Cellular Biochemistry. 53(S17F). 2–17. 18 indexed citations
14.
Dimitrov, Nikolay V., et al.. (1992). Clinical pharmacology studies of Oltipraz — A potential chemopreventive agent. Investigational New Drugs. 10(4). 289–298. 27 indexed citations
15.
Rotmensz, Nicole, G. De Palo, Franca Formelli, et al.. (1991). Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. European Journal of Cancer and Clinical Oncology. 27(9). 1127–1131. 99 indexed citations
16.
Perloff, Marjorie, et al.. (1990). Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects. American Journal of Clinical Nutrition. 51(6). 1082–1087. 23 indexed citations
17.
Costa, Alberto, Winfred F. Malone, Marjorie Perloff, et al.. (1989). Tolerability of the synthetic retinoid fenretinide® (HPR). European Journal of Cancer and Clinical Oncology. 25(5). 805–808. 109 indexed citations
18.
Ellis, Mark, Raymond B. Weiss, Ann H. Korzun, et al.. (1986). Hyperglycemic Complications Associated with Adjuvant Chemotherapy of Breast Cancer A Cancer and Leukemia Group B (CALGB) Study. American Journal of Clinical Oncology. 9(6). 533–536. 12 indexed citations
19.
Perloff, Marjorie & Roger Cardinal. (1982). Figures of Reality: A Perspective on the Poetic Imagination. The Modern Language Review. 77(4). 913–913.
20.
Perloff, Marjorie, et al.. (1978). Charles Olson in Connecticut. The Yearbook of English Studies. 8. 295–295. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026